•
Jun 30, 2024

Sanara MedTech Q2 2024 Earnings Report

Sanara MedTech reported eleventh consecutive record revenue quarter, driven by strong sales in the surgical team and supported by all functional areas, while also strengthening the senior management team.

Key Takeaways

Sanara MedTech reported a record revenue quarter with a 28% increase compared to the previous year, driven by increased sales of soft tissue repair products and market penetration. However, the company experienced a net loss due to increased SG&A costs, executive separation costs, acquisition costs, and higher amortization expenses.

Generated net revenue of $20.2 million, a 28% increase from the prior year period.

The number of facilities where products were sold grew to 800+ compared to 600+ in the same quarter last year.

Reported a net loss of $3.5 million, compared to a net loss of $1.9 million for the prior year quarter.

Generated Adjusted EBITDA of $0.6 million, compared to Adjusted EBITDA of ($0.3) million for the prior year quarter.

Total Revenue
$20.2M
Previous year: $15.8M
+28.0%
EPS
-$0.41
Previous year: -$0.22
+86.4%
Gross Profit
$18.2M
Previous year: $13.6M
+33.8%
Cash and Equivalents
$6.15M
Previous year: $6.06M
+1.5%
Free Cash Flow
-$1.47M
Previous year: -$1.73M
-15.1%
Total Assets
$73.4M
Previous year: $58.3M
+25.9%

Sanara MedTech

Sanara MedTech

Forward Guidance

No specific forward guidance was provided in the press release.